FDA staff say Capricor's deramiocel fails to show clear efficacy for Duchenne, tanking shares 65%+ ahead of this week's adcomm vote.
The FDA is again questioning the efficacy of Capricor’s cell therapy for Duchenne muscular dystrophy, this time ahead of an advisory committee meeting on Wednesday.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics
Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug
FDA scientists question Capricor data; Legend CEO steps down
Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
FDA Scientists Raise Questions About Duchenne Drug
Capricor Therapeutics Stock Dives — 'Complete Fraud' Says Martin Shkreli - Capricor Therapeutics (NASDAQ:
Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback
FDA panel confronting peptide controversy
UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm
